天津医药

天津医药 ›› 2020, Vol. 48 ›› Issue (12): 1230-1235.doi: 10.11958/20200705

• 综述 • 上一篇    下一篇

PD-1/PD-L1抑制剂联合其他免疫检查点抑制剂治疗三阴性乳腺癌的研究进展#br#

崔语恒，赵少荣，刘晶晶，张瑾   

  1. 天津医科大学肿瘤医院，国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床医学研究中心（邮编300060）
  • 收稿日期:2020-03-29 修回日期:2020-08-21 出版日期:2020-12-15 发布日期:2020-12-13
  • 通讯作者: 张瑾 E-mail:zhangjin@tjmuch.com
  • 作者简介:崔语恒（1994），女，硕士在读，主要从事乳腺癌的基础与临床研究
  • 基金资助:
    国家自然科学基金面上项目（81672623）

Research progress of PD-1/PD-L1 inhibitors combined with other immune checkpoint inhibitors in the treatment of triple negative breast cancer

CUI Yu-heng, ZHAO Shao-rong, LIU Jing-jing, ZHANG Jin   

  1. Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China
  • Received:2020-03-29 Revised:2020-08-21 Published:2020-12-15 Online:2020-12-13
  • Contact: ZHANG Jin E-mail:zhangjin@tjmuch.com

PDF (PC)

6258

摘要： 三阴性乳腺癌（TNBC）具有全身转移率高、对常规治疗不敏感以及容易产生耐药性等特点，导致患者的预后较差。随着对机体免疫系统抗肿瘤机制及TNBC免疫特点的不断探究，以程序性细胞死亡蛋白1（PD-1）和程序性死亡蛋白配体1（PD-L1）为代表的免疫检查点抑制剂为TNBC提供了新的治疗方案，但PD-1/PD-L1抑制剂单药治疗的效果不甚理想。本文就PD-1/PD-L1抑制剂联合其他具有不同机制的免疫检查点抑制剂在TNBC患者中的应用进行综述。

关键词: 三阴性乳腺癌, 程序性细胞死亡受体1, 程序性细胞死亡蛋白1, 免疫检查点抑制剂, PD-1/PD-L1抑制剂

Abstract: The poor prognosis of patients with triple-negative breast cancer (TNBC) is related to its high systemic metastasis rate, insensitivity to conventional treatment and easy development of drug resistance. With the continuous exploration of anti-tumor mechanism of immune system and immune characteristics of TNBC, immune checkpoint inhibitors represented by programmed cell death protein 1 (PD-1) and programmed death protein ligand 1 (PD-L1) provide new treatment options for TNBC. However, the effect of PD-1/PD-L1 inhibitor monotherapy is not ideal. Therefore, this article aims to explore the application of PD-1/PD-L1 inhibitors combined with other immune checkpoint inhibitors with different mechanisms in the treatment of TNBC patients.

Key words: triple negative breast neoplasms, programmed cell death 1 receptor, programmed cell death protein 1, immune checkpoint inhibitors, PD-1/PD-L1 inhibitor

中图分类号: